Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study

BACKGROUND: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for patients receiving chemotherapy with FN risk of ≥20% or 10% to 20% with defined risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Rapoport, Bernardo Leon, Aapro, Matti, Paesmans, Marianne, van Eeden, Ronwyn, Smit, Teresa, Krendyukov, Andriy, Klastersky, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154917/
https://www.ncbi.nlm.nih.gov/pubmed/30249215
http://dx.doi.org/10.1186/s12885-018-4838-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154917/
https://www.ncbi.nlm.nih.gov/pubmed/30249215
http://dx.doi.org/10.1186/s12885-018-4838-z

Ejemplares similares